Detalhe da pesquisa
1.
Human papillomavirus 16 E6 antibodies are sensitive for human papillomavirus-driven oropharyngeal cancer and are associated with recurrence.
Cancer
; 123(22): 4382-4390, 2017 Nov 15.
Artigo
Inglês
| MEDLINE | ID: mdl-28950407
2.
MicroRNA-363 targets myosin 1B to reduce cellular migration in head and neck cancer.
BMC Cancer
; 15: 861, 2015 Nov 06.
Artigo
Inglês
| MEDLINE | ID: mdl-26545583
3.
Characterizing patient-reported outcomes in veterans with cirrhosis.
PLoS One
; 15(9): e0238712, 2020.
Artigo
Inglês
| MEDLINE | ID: mdl-32915828
4.
T cell receptor richness in peripheral blood increases after cetuximab therapy and correlates with therapeutic response.
Oncoimmunology
; 7(11): e1494112, 2018.
Artigo
Inglês
| MEDLINE | ID: mdl-30377562
5.
STING activation enhances cetuximab-mediated NK cell activation and DC maturation and correlates with HPV+ status in head and neck cancer.
Oral Oncol
; 78: 186-193, 2018 03.
Artigo
Inglês
| MEDLINE | ID: mdl-29496049
6.
Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals.
Clin Cancer Res
; 24(1): 62-72, 2018 01 01.
Artigo
Inglês
| MEDLINE | ID: mdl-29061643
7.
CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer.
Clin Cancer Res
; 23(3): 707-716, 2017 Feb 01.
Artigo
Inglês
| MEDLINE | ID: mdl-27496866
8.
Characterization of human papillomavirus antibodies in individuals with head and neck cancer.
Cancer Epidemiol
; 42: 46-52, 2016 06.
Artigo
Inglês
| MEDLINE | ID: mdl-27010729
9.
Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients.
Clin Cancer Res
; 19(7): 1858-72, 2013 Apr 01.
Artigo
Inglês
| MEDLINE | ID: mdl-23444227